From Nasdaq.:



Novo Nordisk (NYSE: NVO) is a leading healthcare company with a strong focus on diabetes and weight-loss products. Two of its most promising assets are Ozempic and Wegovy, both of which have shown significant effectiveness in helping people lose weight. The company has seen substantial growth opportunities and a rise in stock value this year, with shares increasing by more than 45%. Despite its $450 billion market cap, Novo Nordisk is expected to grow even further in the coming years, with plans to invest $6 billion in new production facilities to meet the demand for its products.

On the other hand, Meta Platforms (NASDAQ: META), which owns Facebook and WhatsApp, has a market cap of $900 billion. However, the company is facing challenges, including losing popularity among younger users to platforms like TikTok, and incurring significant operating losses from its investment in the metaverse. While Meta Platforms currently has a high valuation, it may not be sustainable in the long run.

The article suggests that Novo Nordisk has better long-term growth prospects than Meta Platforms, and it could potentially overtake Meta Platforms in market cap by 2030. The author advises considering the 10 best stocks for investment, as identified by The Motley Fool Stock Advisor analyst team, which doesn’t currently include Novo Nordisk.



Original: Will Novo Nordisk Be Worth More Than Meta Platforms by 2030?